Pulmonary delivery of antiviral drugs in liposome aerosols

Seminars in Pediatric Infectious Diseases

Volumn 7, Issue 2, 1996, Pages 148-154

  Gilbert, B E ^a   Knight, V ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; RIBAVIRIN;

AEROSOL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; HUMAN; RESPIRATORY TRACT INFECTION; RHINOVIRUS; VIRUS INFECTION;

EID: 0030010199     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1045-1870(96)81012-0     Document Type: Article

References (63)

1. Kellaway IW Farr SJ Liposomes as drug delivery systems to the lung Adv Drug Delivery Rev 5 1990 149 161
2. Taylor KMG Farr SJ Liposomes for drug delivery to the respiratory tract Drug Develop Ind Pharm 19 1993 123 142
3. Wyde PR Six HR Wilson SZ Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes Antimicrob Agents Chemother 32 1988 890 895
4. Gilbert BE Six HR Wilson SZ Small particle aerosols of enviroxime-containing liposomes Antiviral Res 9 1988 355 365
5. Six HR Gilbert BE Wyde PR Liposomes as carriers of enviroxime for use in aerosol therapy of rhinovirus infections Lopez-Berestein G Fidler I Liposomes in the Therapy of Infectious Diseases and Cancer 1989 Alan R. Liss New York 229 238
6. Garcon NM Six HR Frazer J Liposomes of enviroxime and phosphatidylcholine: Defination of the drug-phospholipid interactions Antiviral Res 11 1989 89 98
7. Gregoriadis G Liposome Technology vols 1–3 1984 CRC Press Boca Raton
8. Storm G Oussoren C Peeters PAM Safety of liposome administration Vigo-Pelfrey C Membrane Lipid Oxidation Vol III 1991 CRC Press Boca Raton, FL 239 263
9. Wichert BV Gonzalerothi RJ Straub LE Amikacin liposomes: Characterization, aerosolization, and in vitro activity against Mycobacterium avium-intracellulare in alveolar macrophages Int J Pharm 78 1992 227 235
10. Wasan KM Morton RE Rosenblum MG Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: Role of lipid transfer protein J Pharm Sci 83 1994 1006 1010
11. Schreier H Gonzalerothi RJ Stecenko AA Pulmonary delivery of liposomes J Control Release 24 1993 209 223
12. Knight V Gilbert BE Ribavirin aerosol treatment of influenza Knight V Gilbert BE Infectious Disease Clinics of North America (vol 1: Antiviral Chemotherapy) 1987 Saunders Philadelphia, PA 441 457
13. Niven RW Schreier H Nebulization of liposomes: 1. Effects of lipid composition Pharmaceut Res 7 1990 1127 1133
14. Niven RW Speer M Schreier H Nebulization of liposomes: 2. The effects of size and modeling of solute release profiles Pharmaceut Res 8 1991 217 221
15. 99mtechnetium-labelled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers Int J Pharm 115 1995 209 216
16. (abstr) Knight GM Gilbert BE Waldrep JC Inhalation of a corticosteroid-liposome preparation by normal subjects causes no adverse effects ALS/ATS International Conference 1994
17. Myers MA Thomas DA Straub L Pulmonary effects of chronic exposure to liposome aerosols in mice Exp Lung Res 19 1993 1 19
18. (abstr) Myers MA Niven RW Straub L Alveolar macrophage profiles in mice chronically exposed to liposome aerosols Am Rev Respir Dis 141 1990 A675
19. Thomas DA Myers MA Wichert B Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers Chest 99 1991 1268 1270
20. Canonico AE Plitman JD Coronary JT No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes J Appl Physiol 77 1994 415 419
21. Waldrep JC Keyhani K Black M Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol Chest 105 1994 106 110
22. Knight V Yu CP Gilbert BE Estimating the dosage of ribavirin aerosol according to age and other variables J Infect Dis 158 1988 443 448
23. Giacomelli-Maltoni G Melandri C Prodi V Deposition effeciency of monodisperse particles in human respiratory tract Am Ind Hyg Assoc J 33 1972 603 610
24. DeLong DC Reed SE Inhibition of rhinovirus replication in organ culture by a potential antiviral drug J Infect Dis 141 1980 87 91
25. Ahmad ALM Tyrrell DAJ Synergism between anti-rhinovirus antivirals: Various human interferons and a number of synthetic compounds Antiviral Res 6 1986 241 252
26. Ninomiya Y Aoyama M Umeda I Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 4′,6-dichloroflavan and enviroxime Antimicrob Agents Chemother 27 1985 595 599
27. DeLong DC Effect of enviroxime on rhinovirus infections in humans Leive L Schlessinger D Microbiology 1984 1984 American Society for Microbiology Washington, DC 431 434
28. Higgins PG Barrow GI Al-Nakib W Failure to demonstrate synergy between interferon-α and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers Antiviral Res 10 1988 141 149
29. Levandowski RA Pachucki CT Rubenis M Topical enviroxime against rhinovirus infection Antimicrob Agents Chemother 22 1982 1004 1007
30. Miller FD Monto AS DeLong DC Controlled trial of environxime against natural rhinovirus infections in a community Antimicrob Agents Chemother 27 1985 102 106
31. Hayden FG Gwaltney JM Jr Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection Antimicrob Agents Chemother 21 1982 892 897
32. Phillpots RJ Wallace J Tyrrell DAJ Therapeutic activity of environxime against rhinovirus infection in volunteers Antimicrob Agents Chemother 23 1983 671 675
33. Phillpotts RJ Jones RW DeLong DC The activity of enviroxime against rhinovirus infection in man Lancet 1 1981 1342 1344
34. Turner RB Dutko FJ Goldstein NH Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection Antimicrob Agents Chemother 37 1993 297 300
35. (abstr) Schiff GM Sherwood JR Young EC Prophylactic efficacy of WIN 54954 in prevention of experimental human coxsackievirus A21 infection and illness Antiviral Res 17 suppl 1 1992 92
36. Fox MP Otto MJ McKinlay MA Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug Antimicrob Agents Chemother 30 1986 110 116
37. See DM Tilles JG WIN-54594 treatment of mice infected with a diabetogenic strain of group B coxsackievirus Antimicrob Agents Chemother 37 1993 1593 1598
38. Shepard DA Heinz BA Rueckert RR WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14 J Virol 67 1993 2245 2254
39. Hayden FG Hipskind GJ Woerner DH Intranasal Pirodavir (R77,975) treatment of rhinovirus colds Antimicrob Agents Chemother 39 1995 290 294
40. Kelly JL Albert RK Wood DE Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients Transplantation 59 1995 1144 1147
41. Debs RJ Montgomery AB Brunette EN Aerosol administration of antiviral agents to treat lung infection due to murine cytomegalovirus J Infect Dis 157 1988 327 331
42. Szoka FC Jr Chu CJ Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes Antimicrob Agents Chemother 32 1988 858 864
43. Hostetler KY Parker S Sridhar CN Acyclovir diphosphate dimyristoylglycerol: A phospholipid produrg with activity against acyclovir-resistant herpes simplex virus Proc Natl Acad Sci USA 90 1993 11835 11839
44. Hostetler KY Korba BE Sridhar CN Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice Antiviral Res 24 1994 59 67
45. (abstr) Hostetler KY Aldern KA Kini GD Phosphonoacid prodrugs with greatly increased antiviral activity in HCMV-infected cells, in vitro Antiviral Res 26 1995 A294
46. Shakiba S Freeman WR Floresaguilar M Antiviral effect in human cytomegalovirus-infected cells, pharmacokinetics, and intravitreal toxicology in rabbits of acyclovir diphosphate dimyristoylglycerol Antimicrob Agents Chemother 39 1995 1383 1385
47. Manoharan M Tivel KL Cook PD Lipidic nucleic acids Tetrahedron Lett 36 1995 3651 3654
48. Juliano RL McCullough HN Controlled delivery of an antitumor drug: Localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system J Pharmacol Exp Ther 214 1980 381 387
49. Anderson PM Hanson DC Hasz DE Cytokines in liposomes: Preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferongamma Cytokine 6 1994 92 101
50. Anderson PM Katsnis E Sencer S Depot characteristics and biodistribution of interleukin-2 liposomes Importance of route of administration J Immunother 12 1992 19 31
51. Huland E Heinzer H Huland H Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon α in patients with pulmonary metastatic renal-cell carcinoma: Effective-ness and toxicity of mainly local treatment J Cancer Res Clin Oncol 120 1994 221 228
52. Killion JJ Fishbeck R Bareli M Delivery of interferon to intracellular pathways by encapsulation of interferon into multilamellar liposomes is independent of the status of interferon receptors Cytokine 6 1994 443 449
53. Baumgarth N Brown L Jackson D Novel features of the respiratory tract T-cell response to influenza virus infection: Lung T cells increase expression of gamma interferon mRNA in vivo and maintain high levels of mRNA expression for interleukin-5 (IL-5) and IL-10 J Virol 68 1994 7575 7581
54. Kovacs JA Baseler M Dewar RJ Increses in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection N Engl J Med 332 1995 567 575
55. Rando RF Ojwang J Elbaggari A Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular tetrads J Biol Chem 270 1995 1754 1760
56. Marshall WS Beaton G Stein CA Inhibition of human immunodeficiency virus activity by phosphorodithioate, oligodeoxy-cytidine Proc Natl Acad Sci USA 89 1992 6265 6269
57. Matsukura M Shinozuka K Zon G Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus Proc Natl Acad Sci USA 84 1987 7706 7710
58. Gao W Stein CA Cohen JS Effect of phosphorothioate homo-oligodeoxynucleotides on herpes simplex virus type 2-induced DNA polymerase J Biol Chem 264 1989 11521 11526
59. Gao WY Hanes RN Vazquez-Padua MA Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides Antimicrob Agents Chemother 34 1990 808 812
60. Gao WY Jaroszewski JW Cohen JS Mechanisms of inhibition of herpes simplex virus type 2 growth by 28-mer phosphorothioate oligodeoxycytidine J Biol Chem 265 1990 20172 20178
61. Stein CA Cleary AM Yakubov L Phosphorothiate oligode-oxynucleotides bind to the third variable loop dimain (v3) of human immunodeficiency virus type 1 gp120 Antisense Res Dev 3 1993 19 31
62. McShan WM Rossen RD Laughter AH Inhibition of transcription of HIV-1 in infected human cells by oligodeoxynucleotides designed to form DNA triple helices J Biol Chem 267 1992 5712 5721
63. Wyatt JR Vickers TA Roberson JL Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immuno-deficiency virus envelope-mediated cell fusion Proc Natl Acad Sci USA 91 1994 1356 1360